Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction

M Matthias Müller (PROSION Therapeutics) M Matthias Barone (Leibniz-Forschungsinstitut für Molekulare Pharmakologie) M Maarten van Dinther (Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center) K Kathrin Motzny (Leibniz-Forschungsinstitut für Molekulare Pharmakologie) J Jiang Ren (Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center) J Jenny Eichhorst (Leibniz-Forschungsinstitut für Molekulare Pharmakologie) D Dominik Albat (PROSION Therapeutics) S Slim Chiha (PROSION Therapeutics) M Martin Lehmann (Department of Molecular Physiology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie) R Rudolf Volkmer (Leibniz-Forschungsinstitut für Molekulare Pharmakologie) H Hartmut Oschkinat (Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Straße 10, 13125 Berlin, Germany) H Hans-Günther Schmalz (PROSION Therapeutics) P Peter ten Dijke (Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center) R Ronald Kühne (PROSION Therapeutics)

Abstract

Cancer therapy would benefit from suppressing cancer cell motility in the process of metastasis. Such directed cell migration relies on the propulsive force established by the filamentous actin network within lamellipodia. Proteins of the Ena/VASP family and the WAVE regulatory complex orchestrate lamellar protrusions and therefore provide promising targets for pharmacological interventions. Here, we report a cross-talk between Ena/VASP proteins and WAVE2 that is important for cancer cell extravasation. Mutating the EVH1 domain recognition motif in WAVE2 abrogates chemotaxis of triple-negative MDA-MB-231 breast cancer cells and reduces their extravasation in a zebrafish model. In pilot experiments, orthotopic implantation of these cells into mice led to a reduction in macrometastasis, resulting in prolonged survival. Similarly, intervention by an Ena/VASP-EVH1 inhibitor also reduced metastasis in vivo. Our results suggest that pharmacological interference with the Ena/VASP–WAVE2 interaction may thus reduce metastasis.

Article Details

Volume / Issue Vol. 122, Issue 26
Published July 01, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (14)

M

Matthias Müller

PROSION Therapeutics

M

Matthias Barone

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

M

Maarten van Dinther

Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center

K

Kathrin Motzny

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

J

Jiang Ren

Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center

J

Jenny Eichhorst

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

D

Dominik Albat

PROSION Therapeutics

S

Slim Chiha

PROSION Therapeutics

M

Martin Lehmann

Department of Molecular Physiology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie

R

Rudolf Volkmer

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

H

Hartmut Oschkinat

Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Straße 10, 13125 Berlin, Germany

H

Hans-Günther Schmalz

PROSION Therapeutics

P

Peter ten Dijke

Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center

R

Ronald Kühne

PROSION Therapeutics